Bioversys Ag

BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100

BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026

Data Published in Nature Communications Highlights Unique Mechanism of Action of Alpibectir in Combination with Ethionamide (AlpE)

BioVersys Strengthens Ansamycin Platform and NTM Research Through Collaboration and License Agreement with Hackensack Meridian Health

BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025